Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Reslizumab: First Global Approval.

Literature DB >> 27125787

Reslizumab: First Global Approval.

Abstract

Reslizumab (Cinqair(®)) is a humanised monoclonal interleukin-5 (IL-5) antibody developed by Teva that has been approved in the USA for patients aged ≥18 years as add-on maintenance treatment for severe asthma with an eosinophilic phenotype. IL-5 stimulates the production, activation and maturation of eosinophils and is therefore thought to play a role in the development of bronchial hyper-responsiveness. This article summarizes the milestones in the development of reslizumab leading to this first approval for add-on maintenance treatment of severe asthma with an eosinophilic phenotype.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2016 PMID： 27125787 DOI： 10.1007/s40265-016-0583-2

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

5 in total

1. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.

Authors: Leif Bjermer; Catherine Lemiere; Jorge Maspero; Sivan Weiss; James Zangrilli; Matthew Germinaro
Journal: Chest Date: 2016-04-04 Impact factor: 9.410

2. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial.

Authors: Jonathan M Spergel; Marc E Rothenberg; Margaret H Collins; Glenn T Furuta; Jonathan E Markowitz; George Fuchs; Molly A O'Gorman; Juan Pablo Abonia; James Young; Timothy Henkel; H Jeffrey Wilkins; Chris A Liacouras
Journal: J Allergy Clin Immunol Date: 2011-12-28 Impact factor: 10.793

3. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.

Authors: Jonathan Corren; Steven Weinstein; Lindsay Janka; James Zangrilli; Margaret Garin
Journal: Chest Date: 2016-03-25 Impact factor: 9.410

4. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.

Authors: Mario Castro; James Zangrilli; Michael E Wechsler; Eric D Bateman; Guy G Brusselle; Philip Bardin; Kevin Murphy; Jorge F Maspero; Christopher O'Brien; Stephanie Korn
Journal: Lancet Respir Med Date: 2015-02-23 Impact factor: 30.700

Review 5. Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5.

Authors: R W Egan; D Athwahl; C C Chou; S Emtage; C H Jehn; T T Kung; P J Mauser; N J Murgolo; M W Bodmer
Journal: Int Arch Allergy Immunol Date: 1995 May-Jun Impact factor: 2.749

5 in total

8 in total

Reslizumab: First Global Approval.

1. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.

2. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial.

3. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.

4. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.

Review 5. Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5.

Review 1. Targeted Therapy for Severe Asthma: Identifying the Right Patients.

Review 2. Monoclonal Antibodies for Treatment of Eosinophilic Esophagitis.

Review 3. Essential Mechanisms of Differential Activation of Eosinophils by IL-3 Compared to GM-CSF and IL-5.

Review 4. Therapeutic Strategies of Biologics in Chronic Rhinosinusitis: Current Options and Future Targets.

Review 5. Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis.

Review 6. Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.

Review 7. Pharmacological, Technological, and Digital Innovative Aspects in Rhinology.

Review 8. Current and emerging biologic therapies targeting eosinophilic disorders.